Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
Date:5/17/2010

Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1 /2 clinical study combining MM-111 with Herceptin® (trastuzumab) in patients with advanced Her2 positive breast cancer.

Cambridge, Mass. (PRWEB) May 17, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1 /2 clinical study combining MM-111 with Herceptin® (trastuzumab) in patients with advanced Her2 positive breast cancer.

MM-111 is a bi-specific antibody that targets tumor cells over-expressing ErbB2/HER2. MM-111 is designed to inhibit the signaling between ErbB2/HER2 and ErbB3/HER3 thus disabling the phosphatidylinositol 3-kinase (PI3K) pathway and preventing tumor proliferation.

“Our team is quite excited to test this combination in clinical trials given the preclinical data we have produced showing that MM-111 and Herceptin® have very complementary mechanisms of action,” said Clet Niyikiza, Ph.D., Executive Vice President of Development at Merrimack. “We believe that by combining the two candidates, we have the potential to treat a number of HER2 positive breast cancer patients who are not benefiting from current treatments.”

The Phase 1 /2 study will initially evaluate the human safety and pharmacokinetics of MM-111 in combination with Herceptin® and establish a safe regimen. The Phase 2 portion of the study will then investigate the regimen’s efficacy in the advanced Her2 positive breast cancer patient population. The trial is based on preclinical work showing that MM-111 and Herceptin® positively combine to inhibit the growth of ErbB2 over-expressing breast cancer cells. The Gabrail Cancer Center in Canton, Ohio, Huntsman Cancer Institute in Salt Lake City, Utah, and the Massachusetts General Hospital in Boston, Massachusetts, will part
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
2. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
3. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
4. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
6. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
7. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
8. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
11. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... FREMONT, Calif. , April 1, 2015  ValGenesis ... Software solutions, announced today that it has completed its ... Section 101, Attest Engagements (AICPA, Professional Standards) for the ... 31 st 2014.  ... The ...
(Date:4/1/2015)... , Apr. 1, 2015 Goldman Small ... the small cap and microcap sectors, announced today that ... Inc. (OTCQB – PMCB), a publicly traded clinical stage ... cancer and diabetes. To view the sponsored research article, ... in its entirety, please visit www.GoldmanResearch.com .  ...
(Date:4/1/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... an agreement with inVentiv Health for the operational ... lead compound (BHV-0223). Biohaven is ... stage neuroscience compounds targeting the glutamatergic system. Clinical ...
(Date:4/1/2015)... April 1, 2015  EMD Serono, the U.S. biopharmaceuticals ... , announced today the appointment of Frederick E. ... and Immunology. In this capacity, he will lead the ... projects and collaborations for Rebif ® (interferon beta-1a) ... Dr. Munschauer joins EMD Serono from ...
Breaking Biology Technology:ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 2Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 4Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 2EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 4EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 5
... and flat federal funding of biomedical research, five,important actions ... cost --,can yield dramatic results for patients and the ... (NCI) in a commentary published today by "The,Oncologist." , ... , In the article, James ...
... 07/06 2008 08/07, ... millions millions, ... 14, Other EU Countries 9.7 22 17 11.3 ... 3 10 2.0 4 45, SLIT ...
... Jan. 15 Regado Biosciences, Inc., announced today ... to the position of Senior Vice President, Clinical ... immediately. He will report to David J. ... Officer.Dr. Mazzo stated, "Steven has led clinical programs ...
Cached Biology Technology:National Cancer Institute: Battling Cancer and a Recession 2National Cancer Institute: Battling Cancer and a Recession 3Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded 2Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded 3Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer 2Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer 3
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces its biometric payment technology, ... featured in 2015 "I Want That" International CES Special, ... the DIY Network.   DIY,s "I Want ... site of the 2015 International CES for a firsthand ...
(Date:3/18/2015)... 18, 2015 As mobile payments become ... smart wallets and apps continue to be introduced into the ... the mobile payment industry in focus today are:  NXT-ID, Inc. ... BABA ), Apple Inc. (NASDAQ: AAPL ... Inc. (NASDAQ: FB ) NXT-ID, Inc. ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... its food or wait for dinner to arrive is linked to ... revealed. Prof. Rob McLaughlin has discovered that foraging behaviour of ... in the fish,s brain. "We found that the fish that ... telencephalons than the fish that sit along the shoreline and wait ...
... available in Chinese . College Park, MD (August ... powerful tools in molecular biology today. The devices, which can ... or genetic sequences, are employed in everything from forensic analysis ... Li and colleagues at Simon Fraser University in Burnaby, Canada ...
... Malfunction of a protein has been linked to a form of ... males, says Nasser K. Yaghi, a Texas A&M University magna cum ... research project at Harvard that has been published in the journal ... the condition is detected early in fetal development a treatment could ...
Cached Biology News:Brain size determines whether fish hunters or slackers 2Texas A&M spring graduate contributes to mental retardation research published in Nature 2
... dye terminators, template DNA, primers, salts or ... products have proved critical for both standard ... to work with dye terminator cycle sequencing ... The unique uniformity of the magnetic paeticles ...
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
uncoupling protein 2 (mitochondrial, proton carrier), mRNA (cDNA clone MGC:19567 IMAGE:4335185), complete cds...
Catch and Release® v2.0 Reversible Immunoprecipitation System...
Biology Products: